Table 3.
Compositions Of Rosuvastatin In Situ Gel Formulations Generated By The Box–Behnken Design And The Observed And Predicted Values Of Y1–Y3
| Formulation | X1`(%) | X2` (HLB) | X3` (Ratio) | Y1 (%) | Y2 (%) | Y3 (%) | |||
|---|---|---|---|---|---|---|---|---|---|
| Observed | Predicted | Observed | Predicted | Observed | Predicted | ||||
| ISG 1 | 45 | 15 | 50:50 | 7.29 ± 4.11 | 7.90 | 19.84 ± 2.54 | 19.77 | 26.77 ± 0.94 | 24.44 |
| ISG 2 | 35 | 14 | 20:80 | 19.17 ± 3.82 | 20.22 | 24.11 ± 1.19 | 24.04 | 28.87 ± 1. 58 | 26.70 |
| ISG 3 | 40 | 15 | 20:80 | 20.28 ± 4.26 | 17.75 | 26.56 ± 3.97 | 25.72 | 34.01 ± 1.53 | 34.87 |
| ISG 4 | 35 | 13 | 50:50 | 17.52 ± 3.01 | 16.91 | 29.94 ± 2.63 | 30.01 | 37.93 ± 1.73 | 40.26 |
| ISG 5 | 45 | 14 | 80:20 | 6.07 ± 4.71 | 5.02 | 9.96 ± 3.04 | 10.04 | 14.97 ± 2.63 | 17.14 |
| ISG 6 | 35 | 15 | 50:50 | 12.51 ± 2.68 | 13.99 | 21.46 ± 2.06 | 22.37 | 33.37 ± 1.80 | 34.67 |
| ISG 7 | 40 | 14 | 50:50 | 13.93 ± 3.27 | 16.36 | 23.44 ± 1.83 | 23.34 | 41.76 ± 1.85 | 44.89 |
| ISG 8 | 45 | 14 | 20:80 | 8.2 ± 2.91 | 10.12 | 20.64 ± 1.11 | 21.55 | 32.48 ± 1.47 | 33.95 |
| ISG 9 | 40 | 15 | 80:20 | 10.85 ± 3.84 | 11.28 | 17.05 ± 2.26 | 17.05 | 25.58 ± 1.72 | 25.75 |
| ISG 10 | 45 | 13 | 50:50 | 8.56 ± 3.33 | 7.08 | 19.7 ± 2.13 | 18.79 | 30.72 ± 1.17 | 29.42 |
| ISG 11 | 40 | 13 | 20:80 | 20.00 ± 1.87 | 19.56 | 27.46 ±1.27 | 27.46 | 30.22 ± 1.49 | 30.05 |
| ISG 12 | 40 | 14 | 50:50 | 17.77 ± 1.86 | 16.36 | 24.22 ± 1.02 | 23.34 | 48.97± 1.40 | 44.89 |
| ISG 13 | 40 | 13 | 80:20 | 9.03 ± 2.73 | 11.56 | 21.13 ±1. 39 | 21.97 | 42.0 ± 1.53 | 41.14 |
| ISG 14 | 35 | 14 | 80:20 | 12.76 ± 3. 37 | 10.84 | 22.28 ± 2.91 | 21.37 | 46.94 ± 1.84 | 45.47 |
| ISG 15 | 40 | 14 | 50:50 | 17.39 ± 1.02 | 16.36 | 22.35±1.75 | 23.34 | 43.94 ± 1.22 | 44.89 |
Abbreviations: X1`, polylacticacid-co-Ɛ-caprolactone concentration; X2`, surfactant HLB; X3`, surfactant: PEG 400 ratio; Y1, drug release after 0.5 hr; Y2, drug release after 2 hrs; Y3, drug release after 24 hrs.